CA2929001C - Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease - Google Patents
Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease Download PDFInfo
- Publication number
- CA2929001C CA2929001C CA2929001A CA2929001A CA2929001C CA 2929001 C CA2929001 C CA 2929001C CA 2929001 A CA2929001 A CA 2929001A CA 2929001 A CA2929001 A CA 2929001A CA 2929001 C CA2929001 C CA 2929001C
- Authority
- CA
- Canada
- Prior art keywords
- branched
- straight
- group
- compound
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130162909 | 2013-12-24 | ||
| KR10-2013-0162909 | 2013-12-24 | ||
| KR10-2014-0181951 | 2014-12-17 | ||
| KR1020140181951A KR102344479B1 (ko) | 2013-12-24 | 2014-12-17 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
| PCT/KR2014/012688 WO2015099392A1 (ko) | 2013-12-24 | 2014-12-23 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2929001A1 CA2929001A1 (en) | 2015-07-02 |
| CA2929001C true CA2929001C (en) | 2018-02-20 |
Family
ID=53788040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2929001A Active CA2929001C (en) | 2013-12-24 | 2014-12-23 | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9783551B2 (https=) |
| EP (1) | EP3098224B1 (https=) |
| JP (2) | JP6620096B2 (https=) |
| KR (1) | KR102344479B1 (https=) |
| CN (1) | CN105849111B (https=) |
| AU (1) | AU2014370697B2 (https=) |
| BR (1) | BR112016011281B1 (https=) |
| CA (1) | CA2929001C (https=) |
| CY (1) | CY1121554T1 (https=) |
| DK (1) | DK3098224T3 (https=) |
| ES (1) | ES2718878T3 (https=) |
| HR (1) | HRP20190573T1 (https=) |
| HU (1) | HUE043902T2 (https=) |
| IL (1) | IL245908B (https=) |
| MX (1) | MX374944B (https=) |
| NZ (1) | NZ720328A (https=) |
| PL (1) | PL3098224T3 (https=) |
| PT (1) | PT3098224T (https=) |
| SG (1) | SG11201604371PA (https=) |
| TW (1) | TWI585093B (https=) |
| WO (1) | WO2015099392A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102344479B1 (ko) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
| ES2929931T3 (es) * | 2016-06-29 | 2022-12-05 | Glaceum Inc | Derivado de piranocromenilfenol ópticamente activo y composición farmacéutica que lo comprende |
| KR20180037584A (ko) * | 2016-10-04 | 2018-04-12 | 주식회사 글라세움 | 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체 및 이의 광학 이성질체 합성 방법 |
| TWI804600B (zh) * | 2018-04-03 | 2023-06-11 | 南韓商格雷森伍股份有限公司 | 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法 |
| KR20190116099A (ko) | 2018-04-03 | 2019-10-14 | 주식회사 글라세움 | 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물 |
| KR20200105198A (ko) | 2019-02-28 | 2020-09-07 | 주식회사 글라세움 | 신경계 질환의 예방 또는 치료용 약학적 조성물 |
| KR102692932B1 (ko) | 2019-07-30 | 2024-08-07 | 주식회사 글라세움 | 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법 |
| US20250367163A1 (en) | 2021-06-08 | 2025-12-04 | Glaceum, Inc. | Pharmaceutical composition for preventing or treating degenerative eye diseases |
| CN113616548B (zh) * | 2021-09-02 | 2023-04-28 | 河南科技大学 | 一种水溶性光甘草定包合物及其制备方法 |
| WO2023200189A1 (ko) | 2022-04-12 | 2023-10-19 | 주식회사 글라세움 | 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체의 합성 방법 |
| CN114903879B (zh) * | 2022-06-23 | 2023-10-31 | 东北大学 | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 |
| EP4717265A1 (en) | 2023-01-12 | 2026-04-01 | Glaceum, Inc. | Pharmaceutical composition for preventing or treating degenerative osteoarthritis |
| KR20250081177A (ko) | 2023-11-29 | 2025-06-05 | 한국화학연구원 | Hsg4112 r형을 유효성분으로 포함하는 반려동물의 비만 예방, 개선 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1599602A (zh) | 2001-10-11 | 2005-03-23 | 钟渊化学工业株式会社 | 过氧化物酶体增殖剂应答性受体配体剂及其制备方法 |
| KR100565423B1 (ko) * | 2003-10-20 | 2006-03-30 | 빅 바이오 주식회사 | 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법 |
| JP2006008604A (ja) | 2004-06-25 | 2006-01-12 | Kuraray Co Ltd | イソフラバン誘導体の製造方法 |
| WO2007058480A1 (en) | 2005-11-16 | 2007-05-24 | Md Bioalpha Co., Ltd. | Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin |
| KR102344479B1 (ko) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
-
2014
- 2014-12-17 KR KR1020140181951A patent/KR102344479B1/ko active Active
- 2014-12-23 DK DK14873860.2T patent/DK3098224T3/da active
- 2014-12-23 US US15/037,230 patent/US9783551B2/en active Active
- 2014-12-23 CA CA2929001A patent/CA2929001C/en active Active
- 2014-12-23 JP JP2016540481A patent/JP6620096B2/ja active Active
- 2014-12-23 AU AU2014370697A patent/AU2014370697B2/en active Active
- 2014-12-23 SG SG11201604371PA patent/SG11201604371PA/en unknown
- 2014-12-23 PL PL14873860T patent/PL3098224T3/pl unknown
- 2014-12-23 NZ NZ720328A patent/NZ720328A/en unknown
- 2014-12-23 ES ES14873860T patent/ES2718878T3/es active Active
- 2014-12-23 MX MX2016008429A patent/MX374944B/es active IP Right Grant
- 2014-12-23 HU HUE14873860 patent/HUE043902T2/hu unknown
- 2014-12-23 PT PT14873860T patent/PT3098224T/pt unknown
- 2014-12-23 EP EP14873860.2A patent/EP3098224B1/en active Active
- 2014-12-23 WO PCT/KR2014/012688 patent/WO2015099392A1/ko not_active Ceased
- 2014-12-23 CN CN201480070935.5A patent/CN105849111B/zh active Active
- 2014-12-23 BR BR112016011281-4A patent/BR112016011281B1/pt active IP Right Grant
- 2014-12-23 HR HRP20190573TT patent/HRP20190573T1/hr unknown
- 2014-12-24 TW TW103145316A patent/TWI585093B/zh active
-
2016
- 2016-05-29 IL IL245908A patent/IL245908B/en active IP Right Grant
-
2018
- 2018-03-23 JP JP2018056783A patent/JP2018135343A/ja active Pending
-
2019
- 2019-04-16 CY CY20191100423T patent/CY1121554T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102344479B1 (ko) | 2021-12-29 |
| IL245908B (en) | 2020-08-31 |
| WO2015099392A1 (ko) | 2015-07-02 |
| EP3098224B1 (en) | 2019-01-30 |
| NZ720328A (en) | 2018-02-23 |
| AU2014370697B2 (en) | 2017-01-19 |
| JP2018135343A (ja) | 2018-08-30 |
| SG11201604371PA (en) | 2016-07-28 |
| US20160272650A1 (en) | 2016-09-22 |
| DK3098224T3 (da) | 2019-05-13 |
| AU2014370697A1 (en) | 2016-06-16 |
| CN105849111B (zh) | 2018-05-04 |
| TW201607949A (zh) | 2016-03-01 |
| CY1121554T1 (el) | 2020-05-29 |
| ES2718878T3 (es) | 2019-07-05 |
| EP3098224A1 (en) | 2016-11-30 |
| BR112016011281B1 (pt) | 2021-11-16 |
| JP6620096B2 (ja) | 2019-12-11 |
| CA2929001A1 (en) | 2015-07-02 |
| BR112016011281A2 (https=) | 2017-08-08 |
| TWI585093B (zh) | 2017-06-01 |
| HRP20190573T1 (hr) | 2019-05-17 |
| JP2017501163A (ja) | 2017-01-12 |
| MX374944B (es) | 2025-03-06 |
| US9783551B2 (en) | 2017-10-10 |
| PL3098224T3 (pl) | 2019-07-31 |
| MX2016008429A (es) | 2017-02-23 |
| CN105849111A (zh) | 2016-08-10 |
| PT3098224T (pt) | 2019-04-26 |
| EP3098224A4 (en) | 2017-07-05 |
| KR20150075030A (ko) | 2015-07-02 |
| IL245908A0 (en) | 2016-08-02 |
| HUE043902T2 (hu) | 2019-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2929001C (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| US9340477B2 (en) | Process for production of hydroxystilbene derivative having physiological activity | |
| JP7036871B2 (ja) | 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物 | |
| JP2021527069A (ja) | 肝疾患治療又は予防のための化合物 | |
| JP7195067B2 (ja) | ロズマリン酸誘導体又はその塩 | |
| JP7223477B2 (ja) | Ｔｒｐｖ４活性抑制剤 | |
| HK1227863A1 (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| HK1227863B (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| NZ749461B (en) | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same | |
| KR20180094714A (ko) | 6,7-이치환된 3-(2-히드록시페닐)크로만 유도체 및 대사증후군 또는 염증 질환 치료용 약학 조성물 | |
| HK40004723A (en) | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160427 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241209 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251105 |